Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs

Abstract

Background Systemic inflammation response index (SIRI) has been reported to be an effective blood-based biomarker for predicting prognosis in various kinds of cancer patients. However, the prognostic role of SIRI in advanced lung adenocarcinoma patient remains unclear. Methods The aim of the present study is to evaluate the prognostic role of SIRI in EGFR-mutant advanced lung adenocarcinoma patients treated with first-generation EGFR-TKIs. A total of 245 patients who received gefitinib, erlotinib, or icotinib at the Second Xiangya Hospital were retrospectively evaluated. SIRI was defined as neutrophil count×monocyte/lymphocyte count. The optimal cut-off value was determined according to receiver operation characteristic curve analysis. Characteristics of patients were compared via chi-square test or Fisher’s exact test. Survivals were estimated by the Kaplan–Meier method and compared by the Log rank test. Multivariate analysis was estimated using the Cox proportional hazards model. Results It is showed that high SIRI was associated with male patient, smoker, worse ECOG PS, 19-DEL mutation. Kaplan–Meier survival analysis showed that ECOG PS, brain metastasis, SIRI were significantly correlated with progression-free survival (PFS), and gender, ECOG PS, brain metastasis, NLR and SIRI were significantly correlated with overall survival (OS). Multivariate analysis showed that SIRI and ECOG PS independently predict PFS and OS. Conclusion Our findings indicate that SIRI is an effective and convenient marker for predicting prognosis in advanced EGFR-mutant lung adenocarcinoma patients treated with first-generation TKI.

The Predictive Role of NLR, d-NLR, MLR, and SIRI in COVID-19 Mortality

“…Poorly differentiated and immature neutrophils can be released into a pro-inflammatory environment, which rapidly increases neutrophil generation, thus dNLR is likely to reflect this negative inflammation more comprehensively [ 17 , 19 ]. The systemic inflammatory response index (SIRI) may also reflect the host’s immune and inflammatory balance [ 20 ]. In addition, systemic immune-inflammation index (SII), defined as platelet count × NLR, is effective in reflecting inflammatory status, being a basic biomarker for predicting the prognosis [ 12 ].…”

Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy

“…Hence, SII reflects the balance between host inflammatory and immune response conditions [ 40 ]. Recent evidence suggests that pretreatment SII may serve as a useful prognostic indicator in patients with NSCLC [ 12 , 13 , 41 , 42 , 43 , 44 , 45 , 46 ]. Our results are consistent with those of findings that showed SII is associated with the prognosis of clinical outcomes.…”

A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children

“…In hepatocellular carcinoma, high SII predicted shorter recurrence-free survival and OS (26). In advanced lung adenocarcinoma treated with first-generation EGFR-TKIs, elevated SIRI was correlated with worse ECOG PS, EGFR 19-Del mutation, OS and PFS, SIRI was an independent survival predictor (27). The pathological characteristic of LCH lesions is a vigorous inflammatory cells infiltrate surrounding pathological histiocytes.…”